# A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-cost-comparison-of-infliximab-versus-intravenous-immunoglobulin-for-refractory/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Scarlett Carmen Johnson,Daniel C. Williams,Daniel Brinton,Marshall Chew,Annie N. Simpson,Annie Lintzenich Andrews |
| Citations | 17 |
| DOI | 10.1542/hpeds.2020-0188 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/7769204 |
| OpenAlex ID | https://openalex.org/W3113071757 |
| PMID | 33293266 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Daniel Brinton](https://scholariq.org/researchers/daniel-brinton/)

## Paper primary topic

- [Kawasaki Disease and Coronary Complications](https://scholariq.org/topics/kawasaki-disease-and-coronary-complications/)

## Paper topics

- [Kawasaki Disease and Coronary Complications](https://scholariq.org/topics/kawasaki-disease-and-coronary-complications/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Neonatal and Maternal Infections](https://scholariq.org/topics/neonatal-and-maternal-infections/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.